United States & Sanofi
15 shared events · Importance 4 · Last updated Aug 21, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Sanofi: Sanofi is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
United States: The U.S. gains a new flu vaccine option, potentially improving public health outcomes for older adults.
Sanofi: Sanofi's high-dose flu vaccine served as a comparator in trials; the new mRNA vaccine may compete with its products.
Aug 05, 2026 · 105 articles
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
Sanofi: Sanofi participated in a concurrent private placement, purchasing 500,000 shares for $7.5 million, and has a prior $1.5 billion research collaboration with Scribe. This deepens Sanofi's strategic involvement in gene editing and cardiovascular therapies.
Jul 06, 2026 · 25 articles
Regulatory
United States: A target market for future regulatory approval and collaborations, representing a significant growth opportunity for Pulse.
Sanofi: Already a customer of Pulse's manufacturing, the approval may strengthen their supply relationship.
Aug 20, 2026 · 6 articles
Business
United States: The US approved Awiqli earlier in 2026, contributing to its global rollout.
Sanofi: Sanofi's Lantus faces new competition from Awiqli, which offers less frequent dosing and lower cost per unit.
Jul 09, 2026 · 21 articles
Business
United States: Regulatory jurisdiction where FDA designations were granted and where commercialization rights are included.
Sanofi: Mentioned as a collaborator with Innate, not directly involved in this partnership.
Aug 10, 2026 · 10 articles
Domestic
Sanofi: Sanofi, a hepatitis B vaccine maker, defended its products as safe, and its U.S.-listed shares ended up 1.3%.
Dec 05, 2025 · 7 articles
Domestic
Sanofi: Sanofi is a major insulin maker that has moved to cut the cost of insulin and offers a savings program for people without health insurance.
Apr 02, 2026 · 6 articles
Regulatory
Sanofi: Sanofi is mentioned as a collaborator with Innate Pharma in immuno-oncology.
Apr 02, 2026 · 7 articles
Business
Sanofi: Sanofi, in collaboration with Regeneron Pharmaceuticals, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
Regulatory
Sanofi: Sanofi is mentioned as a biopharmaceutical company with whom Innate Pharma has established collaborations.
Apr 13, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Sanofi interact across events, view sentiment trends, and discover connected entities.
Open Dashboard